# CJC-1295 DAC vs No-DAC (Modified GRF 1-29) in the Research Literature > CJC-1295 DAC vs no-DAC explained: the DAC form binds serum albumin for a 5.8-8.1 day half-life; the no-DAC form (Modified GRF 1-29) is short-acting. The two are routinely conflated. One backbone, two pharmacokinetic lives. The albumin bond is the entire difference — and the single most confused point in the CJC-1295 record. ## CJC-1295 DAC vs no-DAC: one bond decides everything CJC-1295 DAC and the no-DAC form share an identical peptide backbone — the same hGRF(1-29) sequence with the same four protease-resistant substitutions. The only difference is one chemical addition, and it changes how long the molecule survives in the body from minutes to days [2]. The DAC ('Drug Affinity Complex') form carries a maleimidopropionyl linker on a C-terminal lysine. In the bloodstream that linker reacts with a free thiol on serum albumin and forms a covalent peptide-albumin bond [2]. Because albumin circulates for weeks, the conjugated peptide rides along with it — which is why the DAC form's estimated half-life reaches 5.8 to 8.1 days in healthy adults and a single dose elevates growth hormone and IGF-1 for days [1]. In a rat study, the lead albumin-conjugate showed a 4-fold increase in growth-hormone exposure over two hours versus the unconjugated peptide, with peptide still detectable in plasma beyond 72 hours [2]. The no-DAC form lacks that linker entirely, so it stays short-acting. ## Modified GRF (1-29): the short-acting no-DAC form Modified GRF (1-29) is the everyday name for the no-DAC form. It keeps the four substitutions that protect against enzyme degradation but has no albumin-binding moiety, so it behaves much more like native GHRH(1-29): short-acting, cleared in the minutes-to-hours range rather than days. The substitutions buy it stability against DPP-IV; they do not buy it the multi-day duration that only the albumin bond provides. This is why the two forms are not interchangeable. A protocol written for a short-acting peptide assumes frequent dosing and a brief signal; a long-acting albumin-conjugated peptide produces a sustained, days-long elevation from a single administration. Marketing and forums routinely blur the line between them, which is precisely the error this page exists to correct. ## What is CJC-1295 no-DAC (Modified GRF 1-29)? CJC-1295 no-DAC, sold as Modified GRF (1-29), is the tetrasubstituted GHRH(1-29) sequence without the DAC albumin-binding chemistry — short-acting, and frequently conflated with the long-acting DAC version. It is the same backbone, minus the one feature that makes the DAC form last for days. The substitutions remain; the albumin linker is absent. ## What is CJC-1295 with DAC? CJC-1295 with DAC carries a maleimidopropionyl linker that covalently binds circulating serum albumin, extending the plasma half-life toward 5.8 to 8.1 days so a single dose acts for days [1]. The albumin conjugation is the defining feature. It is the engineered solution to the half-life problem that PEGylation and other strategies were also explored to solve for GHRH analogs [3]. ## What is CJC-1295 DAC? CJC-1295 DAC is the albumin-conjugated, long-acting version of the tetrasubstituted GHRH(1-29) analog. The albumin bond is what distinguishes it from the short-acting no-DAC 'Modified GRF 1-29' — same peptide backbone, plus the linker that ties it to serum albumin and stretches its duration into the multi-day range [1][2]. ## The two forms side by side Read against each other, the two forms diverge on exactly one axis and agree on everything else. Both are built on hGRF(1-29). Both carry the four protease-resistant substitutions — D-Ala2, Gln8, Ala15, Leu27 — that block enzymatic cleavage [2]. Both bind the same GHRH receptor and drive the same GH/IGF-1 response in principle. What separates them is duration. The DAC form's estimated half-life is 5.8 to 8.1 days, and a single dose elevates growth hormone and IGF-1 for days, with IGF-1 staying above baseline up to 28 days after multiple doses [1]. The no-DAC form clears in the minutes-to-hours range, producing a brief pulse. That is roughly a several-hundred-fold difference in how long the molecule persists — driven entirely by whether the albumin linker is present. A reader who treats a 'CJC-1295' figure without specifying the form is, in effect, describing two different pharmacokinetic profiles at once. The practical consequence is that any framing built around one form does not transfer to the other. The sustained, smooth, days-long curve people associate with 'CJC-1295' belongs to the DAC version. The short-acting behavior people associate with 'Modified GRF 1-29' belongs to the no-DAC version. They are the same backbone living two different pharmacokinetic lives. ## Why the conflation happens — and why it matters The mix-up is not random; it has a history. Both forms emerged from the same hGRF(1-29) analog work, both are sold under overlapping names, and casual sources often write 'CJC-1295' to mean whichever form they have in mind. Marketing and forums routinely conflate the long-acting DAC version with the short-acting Modified GRF (1-29), and the names themselves invite it — 'CJC-1295' is used loosely for both, while the CAS registry number 863288-34-0 is most consistently attributed to the DAC variant yet sometimes applied to the no-DAC sequence as well. Why it matters is straightforward: the two forms answer different questions. The albumin-conjugation chemistry that defines the DAC form is the same kind of half-life-extension problem that PEGylation was explored to solve for GHRH analogs more broadly [3] — a deliberate engineering choice, not an incidental property. When a source blurs the two, every downstream statement about half-life, duration, and dosing logic inherits the ambiguity. Keeping the distinction sharp is the single most useful thing a reader of this literature can do, which is why this digest gives it a page of its own. --- A calm, tactile reading of the CJC-1295 research record — the pharmacokinetic studies pressed up plainly and the human gaps marked just as clearly, with no clinic behind the name and nothing here dispensed.